Cardiff Oncology, Inc.
CRDF
$1.82
$0.010.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.92% | -17.31% | -24.87% | -21.44% | -9.63% |
| Total Depreciation and Amortization | -4.14% | 11.90% | 34.69% | 71.88% | 136.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.41% | 25.34% | 41.09% | 20.98% | 16.00% |
| Change in Net Operating Assets | -17.24% | -33.91% | -26.16% | -87.63% | -59.91% |
| Cash from Operations | -0.61% | -22.16% | -30.50% | -42.64% | -22.04% |
| Capital Expenditure | 45.00% | 50.00% | 93.55% | 100.00% | 86.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.96% | -121.22% | -167.14% | -116.08% | -62.45% |
| Cash from Investing | -90.22% | -121.49% | -167.97% | -116.39% | -62.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.20% | 360.97% | 2,284.20% | 50,064.49% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.20% | 360.97% | 2,284.20% | 50,064.49% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -214.04% | -32.26% | -340.00% | 49.33% | 461.70% |